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A COMPARISON OF GROUP TESTING ARCHITECTURES FOR COVID-19
TESTING
N. BOTTMAN, Y. COOPER, AND F. JANDA
Abstract. An important component of every country’s COVID-19 response is fast and efficient
testing — to identify and isolate cases, as well as for early detection of local hotspots. For many
countries, producing a sufficient number of tests has been a serious limiting factor in their efforts
to control COVID-19 infections. Group testing is a well-established mathematical tool, which
can provide a serious and rapid improvement to this situation. In this note, we compare several
well-established group testing schemes in the context of qPCR testing for COVID-19. We include
example calculations, where we indicate which testing architectures yield the greatest efficiency
gains in various settings. We find that for identification of individuals with COVID-19, array
testing is usually the best choice, while for estimation of COVID-19 prevalence rates in the total
population, Gibbs–Gower testing usually provides the most accurate estimates given a fixed and
relatively small number of tests. This note is intended as a helpful handbook for labs implementing
group testing methods.
1. Introduction
Group testing is a standard technique for testing a population for a disease with a low incidence
rate, while using fewer tests than if every individual were tested. This schema goes back to at
least 1943, when Dorfman [Dorfman] proposed screening prospective soldiers for syphilis by using
two-stage hierarchical group testing. Over the ensuing decades, the theory of group testing has
been extensively developed, as surveyed in [Hughes-Oliver].
A basic example might proceed like this: instead of using 15 tests for 15 people, use 10 tests
for 10 pooled groups of 5 individual samples each. If, on average, only one of those 10 groups is
positive, the remaining 5 tests could be used to test the individual samples in that positive group.
Therefore, in this example, 15 tests could reach 50 people on average instead of only 15. In general,
when the incidence rate of the disease is low and the test is accurate, this method can provide
accurate results while using many fewer tests.
If the number T of tests at our disposal is fixed, the number of individuals that we can test
depends on the incidence rate. Several groups have worked out the optimal pooling architecture in
various settings. One notable example is the R package binGroup [binGroup], which can systemat-
ically deduce the optimal testing architecture.
In this note, we provide some sample calculations, using current estimates for coronavirus infec-
tion rates, to illustrate how pooled testing can help, both at the individual level and the population
level — that is, both to tell whether a particular person has coronavirus, and to monitor the overall
prevalence rate in the population.
This note is intended as a helpful guide for labs implementing group testing methods. The
authors are happy to help any lab interested in leveraging these techniques to design optimal
architectures given local constraints.
E-mail addresses: bottman@usc.edu, yaim@math.ias.edu, janda@math.ias.edu.
Date: May 8, 2020.
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2. Individual testing
2.1. Architectures.
2.1.1. Dorfman testing (i.e. simple 1-layer group testing). Perhaps the simplest version of group
testing is simple 1-layer group testing. This was first suggested by Dorfman in 1943 as a method for
screening military recruits for syphilis [Dorfman], so we refer to this method as Dorfman testing.
We begin with an overview of Dorfman testing. Suppose that we have a population of n individ-
uals, and we would like to determine, using the minimal number of tests, whether each individual
is positive or negative for a given disease. We proceed as follows:
(1) Group the individuals into n/b batches of b.
(2) For each batch, mix the samples into a single pooled sample.
(3) Using n/b tests, test these pooled samples.
(4) For each pooled sample which tests negative, we deduce that all of the individuals in the
corresponding batch are negative. For each pooled sample which tests positive, we use b
tests to test each individual in the corresponding batch.
When the incidence rate is low, Dorfman testing will use fewer tests than n, which is the number
of tests that we would use if we follows a non-grouped approach and tested every individual.
The optimal batch size b has been studied in [Dorfman] and [Williams], among others. Making
no claims of originality, we now derive the optimal choice of b, supposing that the incidence rate is
ρ. The likelihood of a given batch containing at least one positive individual is P := 1− (1 − ρ)b,
hence the expected number of positive batches will be
n/b∑
i=0
i
(
n/b
i
)
P i(1− P )n/b−i = n
b
P =
n
b
(
1− (1− ρ)b
)
.(1)
The expected number of tests is therefore
T (b) := n
(
1
b
+
(
1− (1− ρ)b
))
.(2)
The minimum is achieved at
b0 =
2W0
(
−1
2
√
− log(1− ρ)
)
log(1− ρ)(3)
≈ 1√
ρ
+
1
2
+
1
8
√
ρ+
1
3
ρ+ · · · ,
where W0 denotes the principal branch of the Lambert W-function (i.e. the product logarithm),
and this minimum value is
T (b0) =

1− exp(2W0 (−12√− log(1− ρ)))+ log(1− ρ)
2W0
(
−1
2
√
− log(1− ρ)
)

n(4)
≈
(
2
√
ρ− 1
2
ρ+
5
12
ρ
√
ρ− 7
24
ρ2 + · · ·
)
n
≈ 2√ρ · n.
Note in particular that b0 depends only on ρ, not on n (!).
We note that when there are significant rates of false positives or false negatives, the optimal
batch size and expected number of tests may differ substantially from the formulas we have derived
here. This situation has been considered in [HanelThurner].
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2.1.2. Early stopping. There is a well known modification of Dorfman testing that was suggested
by Sterrett in [Sterrett]. It is based on the assumption that when a batch turns out positive, most
likely only few individuals in the batch are positive. The method follows Steps 1–3 of Dorfman’s
approach identically (see Section 2.1.1), however proceeds differently with each pooled sample:
(1) For each pooled sample which tests negative, we deduce that all of the individuals in the
corresponding batch are negative.
(2) For each pooled sample which tests positive, we consecutively test the b individuals in the
corresponding batch.
(3) If the test of the sample of the ith individual is negative, move to the next individual. If
the test is positive, pool the remaining b− i samples, and repeat the process with this new
pooled sample.
While it is harder to find formulas for the optimal batch size b and the expected number of
tests per hundred people, Sterrett computed them for many useful values of the incidence rate
ρ. Berrett’s approach offers moderate savings over Dorfman’s in the number of tests. On the
other hand, it is a more complicated process, and takes longer to complete the tests, because
the individuals in positive batches need to be tested sequentially. This becomes more and more
important the larger the batch size b.
2.1.3. Array testing. Finally, we mention an alternative to the simple or hierarchical procedures
described above: array testing. In the simplest variant — described, for instance, as the d = 2 case
in [Hughes-Oliver, §2] — the population is arranged in a 2-dimensional array with √n rows and √n
columns. Each row is tested, and each columns is tested, using a total of 2
√
n tests. If either the
i-th row or the j-th column both test negative, then we can conclude that the (i, j)-th individual
is negative. There are two variants regarding how to treat the individuals whose row and column
both test positive:
(1) Test each such individual, thus establishing precisely which individuals are positive.
(2) Presume that each such individual is positive, reducing the total number of tests used at
the expense of a modest (so long as ρ is small) rate of false positives.
We now calculate, in variant (1), the total number of tests used. To test all rows and columns,
we use 2
√
n tests. To determine the number of tests used in the next stage, we must compute the
expected number of pairs (i, j) such that the i-th row and the j-column both test positive. We
can approximate this by assuming that the number of positive rows and the number of positive
columns are independent:((
1− (1− ρ)
√
n
)√
n
)2
=
(
1− (1− ρ)
√
n
)2
n.(5)
It follows that an approximation for the expected total number of tests is
2
√
n+
(
1− (1 − ρ)
√
n
)2
n.(6)
A somewhat more sophisticated version of array testing, which we might call batched array
testing, proceeds as follows:
(1) Divide the population of n individuals into n/b batches of b individuals.
(2) Apply array testing to each batch.
The advantage of array testing is that the quantity (6) is not of the form f(ρ)n, so by choosing b
carefully, we can optimize the number of individuals tested per test.
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2.2. Examples. The most important features in determining which group testing architectures
are best suited to a given testing scenario are:
• the positive rate ρ of the test population;
• the false positive rate fp of the test;
• the false negative rate fn of the test; and
• the time and cost to run each leg of the test.
We begin with an overview of the current values of these parameters for the COVID-19 qPCR
assay, which is a common way to test for active COVID-19 infections. In the all of the pooling
schemes we will discuss below, we assume just one swab is taken from each patient, and all sub-
samples we refer to are subsamples of the liquid that is held in the lab. We thank Joshua Batson
for help collecting this information [Batson].
• For COVID-19, a wide range of test population positive rates ρ are being observed around
the world. In April 2020, ρ values vary greatly from one community to another, and values
from 0.1%–10% are commonly observed.
• The false positive rate of the COVID-19 qPCR assay is very low, and in this note we do
not discuss variations on group testing that are designed to address false positives.
• The false negative rate of the COVID qPCR assay can be high — as high as 30%. However,
false negatives are overwhelmingly due to lack of virus on the swab collected, and the false
negative rate due to lab error is low. Therefore, in this note we also do not discuss variations
on group testing that are designed to address false negatives.
• In the COVID-19 qPCR assay, a nasal swab is taken from the patient and then the sample
is sent to a lab. There it is immersed in liquid, and a sample of the liquid is plated. Then
the RNA is extracted (this might take 1–2 hours) and PCR is run (another 1–2 hours).
Next, we do some example calculations comparing optimal tests for different variations on the
Dorfman method for three hypothetical COVID-19 testing labs, with expected ρ values of 3 in 10,
3 in 100, and 3 in 1000. We do not consider variations designed to address false positives and false
negatives, because for COVID-19 testing, false positive and false negative rates are low.
architecture optimal batch size individuals tested per test
ρ = 0.3
simple Dorfman 3 1.01
Sterrett testing 2 1.11
batched array testing N/A < 1
ρ = 0.03
simple Dorfman 6 3.03
Sterrett testing 9 3.70
batched array testing 153 3.84
ρ = 0.003
simple Dorfman 19 9.09
Sterrett testing 30 12.50
batched array testing 2694 16.84
3. Prevalence estimation
In the previous section, we focused on the goal of using group testing to classify whether each
individual in a population has a certain disease. On the other hand, there are situations where we
merely want to estimate the proportion of infected individuals.
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In this section, we focus on the latter problem. Just as for classification, we will see that batching
tests can be a valuable tool for the estimation problem. In fact, group testing can be even more
effective in this setting, because we can estimate the number of positive individuals in a positive
group without further testing each individual in the group.
3.1. Description of a simple group-testing algorithm for the estimation problem. We
now describe the simplest way to apply group testing to the estimation problem. This method was
first proposed by Gibbs–Gower [GibbsGower] in 1960 (by the name “multiple-transfer method”)
[GibbsGower], and further studied by Thompson in 1962 [Thompson]. We refer to [Hughes-Oliver,
§ 3.1.2] for further review of the literature.
Suppose that we have a population of n individuals, which we divide into n/b groups of b
individuals. Denote the true incidence rate by p. The likelihood that a given group has at least
one positive individual is then P := 1− (1− p)b.
Next, we test t ≤ n/b of the groups. Denoting the number of groups testing positive by t+, we
obtain an estimate
Pˆ :=
t+
t
for P , and an estimate
pˆ := 1− (1− P )1/b
= 1−
(
1− t+
t
)1/b
for p.
The estimate pˆ is biased, and more precisely an overestimate (when b > 1) with expected value
E(pˆ) = 1−
t∑
i=0
(
i
t
)1/b (t
i
)(
(1− p)b)i(1− (1− p)b)t−i.
The mean squared error (MSE) of the estimate is given by
E((pˆ − p)2) =
t∑
i=0
(
i
t
)2/b(t
i
)
((1− p)b)i(1− (1− p)b)t−i + (p− 1)(p+ 1− 2E(p̂)).
An approximation of this is the asymptotic variance
1− (1− p)b
tb2(1− p)b−2 .
When b = 1, the expected value is E(pˆ) = p, and the MSE specializes to
E((pˆ − p)2) = p(1− p)
t
.
3.2. Examples. In this section, we consider several choices of prevalence rates, and compare the
accuracy of the estimate produced the standard method of testing a random sample of the popu-
lation to two variations. In the first, a larger random sample of the population is tested using the
same number of tests, by using Dorfman testing. In the second, an even larger random sample of
the population is tested by the same number of tests, using the Gibbs-Gower testing methodology
just described. Specifically, we make two comparisons:
• In Table 1, we compare the root mean squared error of the same three testing architectures.
• In Table 2, we compare the number of tests needed to produce a root mean squared error
of less than 15% of the prevalence.
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In both settings, we find that Gibbs–Gower testing outperforms Dorfman testing, which outper-
forms non-group testing.
Table 1. Root MSE of the prevalence estimate produced by two architectures,
under several different true prevalences, if we have 100 total tests at our disposal.
Again, for the two group testing architectures, we used the optimal group size.
prevalence non-group testing Dorfman testing Gibbs–Gower testing
5% 2.18 × 10−2 1.42 × 10−2 6.28 × 10−3 (b = 28)
1% 9.95 × 10−3 4.40 × 10−3 1.28 × 10−3 (b = 143)
0.1% 3.16 × 10−3 7.92 × 10−4 1.29× 10−4 (b = 1428)
0.01% 1.00 × 10−3 1.41 × 10−4 1.29 × 10−5 (b = 13726)
Table 2. How many tests are needed to obtain a root MSE of 15% of the prevalence.
prevalence non-group testing
Gibbs–Gower testing
with group size 5
Gibbs–Gower testing
with optimal group size
5% 845 189 73 (b = 27)
1% 4400 899 76 (b = 138)
0.1% 44400 8899 77 (b ≈ 1320)
0.01% 444400 88899 79 (b ≈ 12150)
The regimes we have considered here span a range of realistic prevalence rates for COVID-19,
and we see that in all of them, Gibbs–Gower testing provides the most accurate estimation of
prevalence rates given a fixed number of tests. At low prevalence rates, the optimal group size for
Gibbs–Gower testing can be quite large — for example, when ρ = 0.01%, the optimal group size
is approximately 12K. Of course, in practical settings, not only are the chemical tests limited and
expensive to run, but sample collection can also be a limiting factor.
Nevertheless, in Table 2 we see that even with a fixed group size of 5, Gibbs–Gower testing
can achieve 15% accuracy with approximately 1/5 the number of tests required by the standard
method. Furthermore, we can optimize the Gibbs–Gower method to minimize any function of the
number of samples and the number of chemical tests. For example, suppose in some locality the
cost to run a chemical test is about ten times the cost to collect each sample. One can optimize
the Gibbs–Gower method to minimize f(s, t) := s + 10t, where s = bt is the number of samples
collected, and t is the number of tests run. We give an example calculation in Table 3.
Table 3. We minimize the quantity bt+10t, subject to the constraint that Gibbs–
Gower testing gives a root MSE of 15% of the prevalence. All numbers are approx-
imate.
prevalence optimal group size total tests total samples
5% 13 93 1209
1% 37 145 5365
0.1% 131 363 47553
Given the importance of daily monitoring of the prevalence rate of COVID-19 in every locality to
allow early detection of local hotspots, Gibbs–Gower testing provides an important tool for regular
prevalence monitoring of COVID-19.
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4. Conclusion
In this note, we have seen that group testing has significant potential to increase COVID-19
testing capacity, given a limited number of tests. We have restricted ourselves to qPCR testing,
which is the standard method for detecting active cases of COVID-19. We expect group testing
could also be helpful in antibody testing for COVID-19, but we defer to a future paper a discussion
of the concerns specific to that application.
We believe that group testing should immediately be deployed in the US. The current capacity in
the U.S. is for testing approximately 250K people per day [COVID] (as of May 5, 2020). Meanwhile,
[JhaTsaiJacobson] have recently suggested that the necessary testing threshold that must be met
before it is possible to safely reopen the economy is the ability to test 500K people per day,
representing a factor of approximately 2. At a positive rate of 10%, the methods we describe here
can allow approximately 2 times as many people be tested with a fixed number of test kits, which
would achieve this target factor of 2.
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